Submit Your Article CMED MEACR meeting
An official publication of the Middle-Eastern Association for Cancer Research
Clinical Cancer Investigation Journal
ISSN Print: 2278-1668, Online: 2278-0513
ARTICLE
Year: 2021   |   Volume: 10   |   Issue: 1   |   Page: 5-10     View issue

Serum level of programmed death-ligand 1 in patients with gastric cancer in Mazandaran Province as a High-Risk Region in Iran


, , , ,
Abstract

Background: Gastric cancer is one of the most common cancers in the world. Programmed death-ligand 1 (PD-L1) is the main ligand of the programmed death-1 receptor that plays a key role in apoptosis in patients with gastric cancer. Materials and Methods: In this study, forty gastric cancer patients and forty healthy controls were enrolled. Serum PD-L1 was measured by enzyme-linked immunosorbent assay. Results: The mean (interquartile range) value of expression level of PD-L1 was 70.6 (36.6–127.3) in patients and 47.7 (29.9–92.1) in controls. There were no significant differences in PD-L1 expression between the two groups and tumor characteristics, but there was a statistically significant difference between the high expression level of PD-L1 and gastric cancer development (P = 0.044, odds ratio = 2.77, 95% confidence interval = 1.12–6.86). Conclusions: PD-L1 level increases in gastric cancer patients, so it could be used as a predictor factor.

Cite this article
Vancouver
Shekarriz R, Hedayatizadeh-Omran A, Amjadi O, Alizadeh-Navaei R, Godazandeh G. Serum level of programmed death-ligand 1 in patients with gastric cancer in Mazandaran Province as a High-Risk Region in Iran. Clin Cancer Investig J. 2021;10(1):5-10. https://doi.org/10.4103/ccij.ccij_128_20
APA
Shekarriz, R., Hedayatizadeh-Omran, A., Amjadi, O., Alizadeh-Navaei, R., & Godazandeh, G. (2021). Serum level of programmed death-ligand 1 in patients with gastric cancer in Mazandaran Province as a High-Risk Region in Iran. Clinical Cancer Investigation Journal, 10(1), 5-10. https://doi.org/10.4103/ccij.ccij_128_20

Copyright © 2024 Clinical Cancer Investigation Journal, All rights are reserved and for all open access contents, the Creative Commons licensing terms apply.
Online since 01 December, 2011
Creative Commons License 
ISSN Print: 2278-1668, Online: 2278-0513